4:00 PM EDT
The President makes an announcement on Significant Medical and Scientific Findings for America's Children
Roosevelt Room
White House Press Pool
https://rollcall.com/factbase/trump/calendar/
https://www.youtube.com/watch?v=Y3iaOfk58cU
https://x.com/i/broadcasts/1LyxBXmQObMGN
3:00 PM EDT
LIVE: Pres. Trump Makes Announcement on Significant Medical Findings for American Children - 9/22/25
Right Side Broadcasting Network
https://rumble.com/v6zbaog-live-pres.-trump-makes-announcement-on-significant-medical-findings-for-ame.html
7:00 PM EDT
National Park Service @NatlParkService - Fat Bear Week Bracket Reveal
https://x.com/NatlParkService/status/1970119364411076964
https://explore.org/livecams/brown-bears/brooks-live-chat
Voting starts TOMORROW!!
https://x.com/NatlParkService/status/1970119364411076964
https://www.youtube.com/watch?v=CN3kdasgN2I
NEW
September 23, 2025
6:40 AM EDT
Launch coverage of three space weather missions: NASA’s Interstellar Mapping and Acceleration Probe (IMAP); NASA’s Carruthers Geocorona Observatory; and the National Oceanic and Atmospheric Administration (NOAA) Space Weather Follow On L1 Mission (SWFO-L1.) Launch is scheduled for 7:32 a.m. Stream on NASA+, Amazon Prime, YouTube
National Aeronautics and Space Administration (NASA)
https://www.nasa.gov/events/
https://www.nasa.gov/live/
https://plus.nasa.gov/scheduled-video/three-new-missions-launch-to-track-space-weather/
https://www.youtube.com/watch?v=vNRrfamTT4k
tomorrow
9:00 AM EDT
543rd Meeting, 29th Session, Committee on Enforced Disappearances (CED) - Consideration of Benin
United Nations
https://webtv.un.org/en/asset/k1u/k1u6ya441f
-
8:30 AM EDT
LIVE: President Trump Gives a Major Address to the United Nations General Assembly in NYC - 9/23/25
Right Side Broadcasting Network
https://rumble.com/v6zbdas-live-president-trump-gives-a-major-address-to-the-united-nations-general-as.html
tomorrow
Kenvue says Tylenol is safe, but stock hits record low ahead of Trump speech
President Trump is expected to speak on scientific findings linking acetaminophen use during pregnancy to autism
Sept. 22, 2025 at 2:46 p.m. ET
https://www.marketwatch.com/story/kenvue-says-tylenol-is-safe-but-stock-hits-record-low-ahead-of-trump-speech-c56b8d29
The Chicago Tylenol Murders
Forty years ago today, a series of grim deaths in the Chicago metropolitan area gripped the nation, changing how American consumers buy over-the-counter medicine and the way public health officials respond to crisis situations.
https://www.chicagohistory.org/tylenol-murders/
Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis
J Pers Med
. 2021 Nov 3;11(11):1141.
doi: 10.3390/jpm11111141
Abstract
The cerebral folate receptor alpha (FRα) transports 5-methyltetrahydrofolate (5-MTHF) into the brain; low 5-MTHF in the brain causes cerebral folate deficiency (CFD). CFD has been associated with autism spectrum disorders (ASD) and is treated with d,l-leucovorin (folinic acid). One cause of CFD is an autoantibody that interferes with the function of the FRα. FRα autoantibodies (FRAAs) have been reported in ASD. A systematic review was performed to identify studies reporting FRAAs in association with ASD, or the use of d,l-leucovorin in the treatment of ASD. A meta-analysis examined the prevalence of FRAAs in ASD. The pooled prevalence of ASD in individuals with CFD was 44%, while the pooled prevalence of CFD in ASD was 38% (with a significant variation across studies due to heterogeneity). The etiology of CFD in ASD was attributed to FRAAs in 83% of the cases (with consistency across studies) and mitochondrial dysfunction in 43%. A significant inverse correlation was found between higher FRAA serum titers and lower 5-MTHF CSF concentrations in two studies. The prevalence of FRAA in ASD was 71% without significant variation across studies. Children with ASD were 19.03-fold more likely to be positive for a FRAA compared to typically developing children without an ASD sibling. For individuals with ASD and CFD, meta-analysis also found improvements with d,l-leucovorin in overall ASD symptoms (67%), irritability (58%), ataxia (88%), pyramidal signs (76%), movement disorders (47%), and epilepsy (75%). Twenty-one studies (including four placebo-controlled and three prospective, controlled) treated individuals with ASD using d,l-leucovorin. d,l-Leucovorin was found to significantly improve communication with medium-to-large effect sizes and have a positive effect on core ASD symptoms and associated behaviors (attention and stereotypy) in individual studies with large effect sizes. Significant adverse effects across studies were generally mild but the most common were aggression (9.5%), excitement or agitation (11.7%), headache (4.9%), insomnia (8.5%), and increased tantrums (6.2%). Taken together, d,l-leucovorin is associated with improvements in core and associated symptoms of ASD and appears safe and generally well-tolerated, with the strongest evidence coming from the blinded, placebo-controlled studies. Further studies would be helpful to confirm and expand on these findings.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8622150/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8622150/pdf/jpm-11-01141.pdf
Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial
Frye, R., Slattery, J., Delhey, L. et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry 23, 247–256 (2018). https://doi.org/10.1038/mp.2016.168
Abstract
We sought to determine whether high-dose folinic acid improves verbal communication in children with non-syndromic autism spectrum disorder (ASD) and language impairment in a double-blind placebo control setting. Forty-eight children (mean age 7 years 4 months; 82% male) with ASD and language impairment were randomized to receive 12 weeks of high-dose folinic acid (2 mg kg−1 per day, maximum 50 mg per day; n=23) or placebo (n=25). Children were subtyped by glutathione and folate receptor-α autoantibody (FRAA) status. Improvement in verbal communication, as measured by a ability-appropriate standardized instrument, was significantly greater in participants receiving folinic acid as compared with those receiving placebo, resulting in an effect of 5.7 (1.0,10.4) standardized points with a medium-to-large effect size (Cohen’s d=0.70). FRAA status was predictive of response to treatment. For FRAA-positive participants, improvement in verbal communication was significantly greater in those receiving folinic acid as compared with those receiving placebo, resulting in an effect of 7.3 (1.4,13.2) standardized points with a large effect size (Cohen’s d=0.91), indicating that folinic acid treatment may be more efficacious in children with ASD who are FRAA positive. Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group. There was no significant difference in adverse effects between treatment groups. Thus, in this small trial of children with non-syndromic ASD and language impairment, treatment with high-dose folinic acid for 12 weeks resulted in improvement in verbal communication as compared with placebo, particularly in those participants who were positive for FRAAs.
https://www.nature.com/articles/mp2016168.pdf
https://www.nature.com/articles/mp2016168
Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder
Semin Pediatr Neurol
. 2020 Oct:35:100835.
doi: 10.1016/j.spen.2020.100835. Epub 2020 Jun 25.
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder that currently has no approved medical therapy to address core symptoms or underling pathophysiological processes. Several compounds are under development that address both underlying pathophysiological abnormalities and core ASD symptoms. This article reviews one of these treatments, d,l-leucovorin calcium (also known as folinic acid) for treatment of folate pathway abnormalities in children with ASD. Folate is a water-soluble B vitamin that is essential for normal neurodevelopment and abnormalities in the folate and related pathways have been identified in children with ASD. One of these abnormalities involves a partial blockage in the ability of folate to be transported into the brain utilizing the primary transport mechanism, the folate receptor alpha. Autoantibodies which interfere with the function of the folate receptor alpha called folate receptor alpha autoantibodies have been identified in 58%-76% of children with ASD and independent studies have demonstrated that blood titers of these autoantibodies correlate with folate levels in the cerebrospinal fluid. Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with ASD, especially those positive for folate receptor alpha autoantibodies. This article reviews the current evidence for treating core and associated symptoms and underlying pathophysiological mechanisms in children with ASD with d,l-leucovorin.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7477301/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7477301/pdf/nihms-1618819.pdf
Explainer: Why is leucovorin being considered as an autism treatment?
September 22, 20254:51 PM EDT
Sept 22 (Reuters) - On Monday, the U.S. Food and Drug Administration published a notice to the Federal Register ahead of a speech by President Donald Trump, approving a version of leucovorin made by GlaxoSmithKline (GSK.L)
, opens new tab that the company had previously withdrawn from the FDA's consideration when it stopped manufacturing the drug.
The FDA cited a review of the use of leucovorin in 40 patients with a rare metabolic disorder called cerebral folate deficiency that can lead to a range of neurological symptoms, some of which are seen in people with autism.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Here’s what is known about leucovorin and autism.
WHAT IS LEUCOVORIN?
Leucovorin, also known as folinic acid, is a form of folate, an essential B vitamin, or B9.
https://www.reuters.com/business/healthcare-pharmaceuticals/why-is-leucovorin-being-considered-an-autism-treatment-2025-09-22/